 Moderna, Inc. packed more punches against its critics as it delivered surprisingly positive results on its personalized cancer vaccine study with Mercks Keytruda. However, BioNTechs more ambitious approach to its cancer vaccine could pack a serious threat and outdo Modernas strategy. 